Most people think of acid reflux as a straightforward problem. Acid goes up, you feel the burn, you take an antacid or a PPI, and you move on. For a lot of people, that is roughly how it works. But for a surprisingly large group, that simple model breaks down. The PPI does not help. The symptoms do not match the textbook. The endoscopy looks normal but the burning persists. Or the opposite happens: significant esophageal damage shows up in someone who barely noticed any symptoms. GERD, gastroesophageal reflux disease, turns out to be far more complicated than the antacid commercials would have you believe. Understanding that complexity matters because it determines whether you get the right treatment or spend years on medications that are not addressing your actual problem.
The GERD spectrum: it is not one disease
The modern understanding of reflux-related conditions places them on a spectrum rather than treating GERD as a single entity. At one end, you have functional heartburn, where symptoms are present but there is no abnormal acid exposure and no correlation between symptoms and reflux events. Moving along the spectrum, you encounter reflux hypersensitivity, where acid exposure is normal but symptoms do correlate with reflux episodes, suggesting the esophageal nerves are overly sensitive to normal stimuli. Then comes non-erosive reflux disease (NERD), where there is abnormal acid exposure but no visible damage on endoscopy. Erosive esophagitis involves actual mucosal breaks visible during endoscopy. And at the far end sits Barrett's esophagus, where chronic acid exposure causes the esophageal lining to change its cellular makeup in a process called intestinal metaplasia (Gyawali et al., 2018).
This spectrum matters clinically because each point on it responds differently to treatment. Erosive esophagitis responds well to PPIs. NERD responds less consistently. Reflux hypersensitivity responds poorly to acid suppression alone. And functional heartburn typically does not respond to PPIs at all, because acid is not the problem (Aziz et al., 2016).
âšī¸Roughly 70 percent of patients with reflux symptoms have NERD, meaning their endoscopy shows no visible damage. A normal-looking esophagus does not rule out reflux disease, but it also does not confirm it. Further testing may be needed to determine what is actually driving your symptoms.
Why PPIs fail for so many people
Proton pump inhibitors are the most prescribed medications for GERD, and they are genuinely effective for acid-mediated disease. They reduce gastric acid production by blocking the hydrogen-potassium ATPase pump in parietal cells, which is the final step in acid secretion. For erosive esophagitis, PPIs heal mucosal damage in 80 to 90 percent of cases within 8 weeks (Kahrilas et al., 2008). That is a strong track record.
But studies consistently show that 30 to 40 percent of patients taking PPIs for GERD symptoms continue to have inadequate symptom control (Fass et al., 2009). This is a massive gap between expectation and reality. Several factors explain it.
- The symptoms are not caused by acid at all. In reflux hypersensitivity and functional heartburn, the esophageal nerves are generating pain signals in response to normal or near-normal stimuli. Reducing acid does not address nerve sensitivity.
- Non-acid reflux. Some patients have weakly acidic or non-acidic refluxate (bile, pepsin, other gastric contents) that causes symptoms. PPIs reduce acid but do not prevent reflux of other stomach contents.
- Incorrect diagnosis. Some patients labeled with GERD actually have eosinophilic esophagitis, achalasia, or esophageal motility disorders that mimic reflux symptoms but require entirely different treatment.
- Dosing or timing issues. PPIs work best when taken 30 to 60 minutes before meals. Many patients take them at the wrong time, which reduces their effectiveness.
- Nocturnal acid breakthrough. Even on twice-daily PPIs, some patients experience periods of acid secretion during the night that can cause symptoms (Peghini et al., 1998).
Reflux hypersensitivity: when normal reflux feels abnormal
Reflux hypersensitivity is a concept that has become increasingly important in understanding PPI-refractory symptoms. These patients have normal acid exposure on pH monitoring, meaning the amount of acid reaching their esophagus is within the normal range. However, when you look at symptom-reflux correlation, their symptoms do line up with reflux events. In other words, small amounts of normal reflux that would not bother most people are triggering significant symptoms in these patients.
The mechanism is thought to involve peripheral and central sensitization of the esophageal nerve pathways. Stress, anxiety, sleep disruption, and prior esophageal injury can all lower the threshold at which reflux events produce symptoms. This is directly analogous to how visceral hypersensitivity works in IBS and functional dyspepsia. The organ itself is not diseased, but the pain signaling system is turned up too high (Aziz et al., 2016).
For these patients, further escalation of acid suppression is unlikely to help. Treatment instead focuses on neuromodulators (low-dose tricyclic antidepressants or SSRIs), behavioral interventions, and sometimes diaphragmatic breathing exercises, which have shown benefit in small trials by strengthening the crural diaphragm that supports the lower esophageal sphincter (Eherer et al., 2012).
Barrett's esophagus: the serious end of the spectrum
Barrett's esophagus represents the far end of the GERD spectrum and is the main reason chronic reflux is taken seriously from a cancer prevention standpoint. In Barrett's, the normal squamous cell lining of the lower esophagus is replaced by columnar epithelium with intestinal metaplasia. This is the body's adaptation to chronic acid exposure, but it comes with a cost: Barrett's is a precancerous condition that increases the risk of developing esophageal adenocarcinoma.
The actual cancer risk is lower than many people fear. The annual progression rate from non-dysplastic Barrett's to esophageal adenocarcinoma is approximately 0.5 percent per year (Hvid-Jensen et al., 2011). When dysplasia (precancerous cellular changes) is present, the risk increases substantially, and endoscopic intervention becomes appropriate. Current guidelines recommend surveillance endoscopy at intervals determined by the degree of dysplasia, with endoscopic eradication therapy for confirmed dysplasia (Shaheen et al., 2016).
Risk factors for Barrett's include long-standing GERD (typically more than 5 to 10 years of symptoms), male sex (roughly 2 to 3 times more common in men), age over 50, central obesity, Caucasian ethnicity, family history of Barrett's or esophageal adenocarcinoma, and smoking. If you have multiple risk factors and long-standing reflux, a screening endoscopy is worth discussing with your doctor (Rubenstein et al., 2015).
â ī¸Barrett's esophagus is not a reason to panic, but it is a reason to get screening if you have had chronic reflux for years, especially if you are male, over 50, or have a family history. Early detection of dysplasia allows for endoscopic treatment before cancer develops.
Getting the right diagnosis: the role of pH and impedance testing
If PPIs are not working and your endoscopy is normal, the next step in the diagnostic workup is typically ambulatory reflux monitoring. This involves either a wireless pH capsule (Bravo) attached to the esophageal wall or a catheter-based pH-impedance probe placed through the nose, both worn for 24 to 96 hours while you go about your normal activities. The test measures how much acid reaches your esophagus, how many reflux events occur (including non-acid reflux), and whether your symptoms correlate with those events.
This testing is best performed off PPI therapy (after a 7-day washout) when the question is whether you actually have pathological reflux. If you have already been diagnosed with GERD and the question is whether PPI-refractory symptoms are due to breakthrough acid, the test can be done on therapy. The Lyon Consensus (Gyawali et al., 2018) provides clear thresholds for interpreting results and categorizing patients into the different diagnostic buckets described earlier.
This diagnostic precision matters because it determines treatment direction. If pH testing confirms pathological acid exposure despite PPI therapy, options include adding nighttime H2 blockers, antireflux surgery (fundoplication), or magnetic sphincter augmentation. If pH testing is normal, acid is not the problem, and the focus shifts to neuromodulatory approaches.
What helps with tracking reflux patterns?
Whether you are trying to figure out your triggers, preparing for a pH study, or monitoring treatment response, keeping a symptom log can be genuinely useful. Recording what you ate, when symptoms occurred, their severity, body position at the time, and stress levels creates a dataset that helps clinicians interpret your case more accurately. Tools like GLP1Gut can structure this tracking so you can share clear patterns with your gastroenterologist rather than relying on memory during a 15-minute appointment.
Tracking is especially valuable during a PPI trial, as it helps distinguish between genuine treatment failure and incomplete adherence or incorrect timing. It is also helpful for identifying non-dietary triggers like stress, late eating, or body position that may be contributing more than specific foods.
Moving beyond the one-size approach
The broader message here is that reflux-related conditions deserve the same diagnostic nuance we now apply to other GI disorders. Just as IBS has been subtyped, and just as functional dyspepsia has been split into EPS and PDS, the world of reflux symptoms needs to be disaggregated. A patient with erosive esophagitis needs different care than a patient with reflux hypersensitivity, and both need different care than a patient with functional heartburn. Lumping them all under 'GERD' and prescribing the same PPI does a disservice to the significant number of patients for whom that approach simply does not work.
If you have been on a PPI for months or years without satisfactory improvement, or if you have been told you have GERD but the diagnosis was based solely on symptoms without any objective testing, it may be time to ask harder questions. What subtype of reflux do I have? Would pH testing change my management? Are there non-acid-suppressive treatments that might address my specific pattern? These are reasonable questions, and a good gastroenterologist will take them seriously.
Is it safe to take PPIs long-term?
For patients with confirmed acid-mediated GERD (especially erosive esophagitis or Barrett's esophagus), the benefits of long-term PPI therapy generally outweigh the risks. Observational studies have raised concerns about associations with kidney disease, bone fractures, C. difficile infection, and micronutrient deficiencies, but these associations are weak and have not been confirmed as causal in randomized trials. The key issue is whether PPIs are indicated for your specific condition. If you have functional heartburn or reflux hypersensitivity, long-term PPIs provide little benefit and the risk-benefit equation shifts (Freedberg et al., 2017).
Can GERD be cured without medication?
For mild reflux, lifestyle modifications can sometimes provide adequate control. Weight loss (in patients with overweight or obesity), elevating the head of the bed, avoiding eating within 3 hours of bedtime, and reducing known triggers can all help. However, for moderate to severe erosive disease or Barrett's, ongoing treatment is usually necessary. Antireflux surgery (fundoplication or magnetic sphincter augmentation) can provide a medication-free option for selected patients with objectively confirmed reflux.
What is the difference between GERD and LPR (laryngopharyngeal reflux)?
LPR refers to reflux that reaches the larynx and pharynx, causing symptoms like chronic throat clearing, hoarseness, cough, and a sensation of a lump in the throat. LPR and GERD overlap, but many patients with suspected LPR have normal acid exposure on testing. The diagnosis of LPR is controversial, and ENT and GI specialists sometimes disagree on how to define and treat it. pH testing with proximal sensors can help clarify the diagnosis.